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Previous studies have shown that human papillomavirus (HPV) E4 proteins undergo oligomerisation, although the precise
sequences involved have not been identified. Using the yeast two-hybrid system we have identified HPV 1 E4 sequences that
are critical to multimerisation. Fusion proteins were created by linking wild-type and mutant E4 proteins to a LexA
DNA-binding domain or a B42 transactivation domain. HPV 1 E4:E4 interactions were examined by expression of these fusion
proteins in Saccharomyces cerevisiae. This assay showed that (1) amino acid residues 95 to 115 at the carboxy-terminus
were critical for oligomerisation and (2) hydrophobic residues (isoleucine 107, phenylalanine 114) in this domain are major
determinants in the formation of oligomers. Interestingly, the carboxy-terminal domain shares homology with other E4
proteins of cutaneous HPV types and, furthermore, positions 107 and 114 are conserved residues. Substitution of the
conserved aspartate amino acids (residues 110 and 112) did not abrogate E4 oligomerisation. Chemical cross-linking of wart
and recombinant (baculovirus-expressed) HPV 1 E4 protein indicated that in solution this viral protein forms complexes
consistent in size with either trimers or tetramers. These complexes were resistant to urea denaturation and are not
dependent on the formation of disulphide linkages. A mutant protein containing a deletion of residues 110 to 115 was unable
to form oligomers following cross-linking supporting a role for this region in mediating E4:E4 interactions. We conclude that
oligomerisation of the HPV 1 E4 protein is likely to be mediated by carboxy-terminal residues and that conserved hydrophobic
residues of this domain play a major role in E4 oligomerisation. © 1998 Academic Press
INTRODUCTION
In papillomavirus (PV)-induced hyperproliferative le-
sions the predominant viral messenger RNA transcript
detected is a product of an in-frame splice of two exons
from the E1 and E4 open reading frames and terminates
at the early region polyadenylation site (Baker and How-
ley, 1987; Chow et al., 1987a,b; Nasseri et al., 1987;
Stamps and Campo, 1988; Stoler et al., 1989; Crum et al.,
1990; Palermo-Dilts et al., 1990; Higgins et al., 1992). The
E1 exon, which encodes only five amino acids, is derived
from the 59 end of the gene and forms the N-terminus of
the E1∧E4 protein (Nasseri et al., 1987; Doorbar et al.,
1988). The expression of the E4 protein is largely re-
stricted to the cytoplasm of cells of the suprabasal epi-
thelium and, in particular, to cells permissive for vegeta-
tive viral DNA replication and capsid protein synthesis
(Doorbar et al., 1986; Breitburd et al., 1987; Crum et al.,
1990; Brown et al., 1995). Although a role in the produc-
tive phase of the PV life cycle is most likely (Doorbar et
al., 1986; Breitburd et al., 1987; Neary et al., 1987) a
precise function has yet to be defined for this viral pro-
tein. An association between E4 proteins and the keratin
cytoskeleton of cultured epithelial cells (Doorbar et al.,
1991; Roberts et al., 1993; Rogel-Gaillard et al., 1993;
Sterling et al., 1993) may be an indication that this protein
functions to alter the normal keratinisation process of the
infected keratinocyte, possibly to allow virus egress
(Doorbar et al., 1991).
Much of our biochemical knowledge of the E4 proteins
has come from the study of the human papillomavirus
(HPV) 1 protein, primarily because of the high level of E4
protein in HPV 1-induced cutaneous warts (the E4 pro-
tein represents up to one-third of the total wart protein)
(Doorbar et al., 1986; Breitburd et al., 1987). The major
E4-encoded polypeptides of HPV 1 comprise a doublet of
molecular weights 16/17 kDa. Minor species of 32/34,
21–23, and 10–11 kDa are also detected at variable levels
by SDS–polyacrylamide gel electrophoresis (SDS-PAGE).
The 17-kDa species is the mature E1∧E4 polypeptide.
The 16-, 11-, and 10-kDa proteins represent proteolytic
fragments of the E1∧E4 protein which lack N-terminal
amino acid residues and, for the 10- and 11-kDa species,
possibly C-terminal sequences as well (Doorbar et al.,
1988; Roberts et al., 1994a). Additional posttranslational
modifications of the HPV 1 E4 protein include phosphor-
ylation (Breitburd et al., 1987; Grand et al., 1989), multim-
erisation (Doorbar et al., 1988, 1996), and binding of the
divalent metal ion zinc (Roberts et al., 1994b). The 32/
34-kDa HPV 1 E4 species represent homodimers of the
16- and 17-kDa proteins, while the 21/23-kDa proteins
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appear to be heterodimers formed by the proteolytic
fragments (Doorbar et al., 1988). Multiple high-molecular-
weight E4 species are also detected following SDS–
PAGE analysis of E4 proteins of other PV types, suggest-
ing that oligomerisation is a common structural
characteristic of these viral proteins (Doorbar et al., 1989;
Jareborg and Burnett, 1991; Tomita et al., 1991; Pray and
Laimins, 1995; Roberts et al., 1997). Previous studies
have indicated that the C-terminal half of the HPV 1 E4
protein is likely to be involved in oligomerisation (Door-
bar et al., 1988, 1996; Roberts et al., 1994b). However,
which amino acid residues mediate self-association and
the relationship between oligomerisation and E4 func-
tion is not known.
To continue our study of the relationship between E4
structure and function we have applied a genetic
method, based on the LexA two-hybrid system (Gyuris et
al., 1993; Golemis et al., 1994), to determine the structural
requirements for oligomerisation of the HPV 1 E4 protein.
The two-hybrid system relies upon protein–protein inter-
actions to reconstitute an active DNA binding–transcrip-
tion activation complex in the yeast, Saccharomyces cer-
evisiae. HPV 1 E4:E4 interactions were characterised by
expression of fusion proteins created by linking wild-type
and mutant E4 proteins to a LexA DNA-binding domain
or a B42 activation domain. This study has demonstrated
that C-terminal sequences, residues 95 to 115, play a
critical role in oligomerisation of the HPV 1 E4 protein in
vivo. Amino acids 110 to 115 represent a conserved motif
between E4 proteins of cutaneous HPV types (Roberts et
al., 1994a) and a mutant protein which lacks this motif
fails to form dimers following chemical cross-linking.
RESULTS
Detection of HPV 1 E4 oligomeric interactions using
the yeast two-hybrid system
The yeast two-hybrid system is a genetic screen used
for detecting protein–protein interactions. To determine
whether this system could detect HPV 1 E4 oligomeric
interactions the HPV 1 E1∧E4 coding sequence was
inserted into the yeast vectors pEG202 and pJG4-5 for
expression of E4 as fusions to the LexA DNA-binding
domain and the B42 transcription activation domain, re-
spectively (Fig. 1). Yeast transformed with both the
LexA–E4 and the B42–E4 constructs showed unambigu-
ously high levels of b-galactosidase activity in liquid
culture assays performed using o-nitrophenyl b-D-galac-
toside as a substrate (Table 1). Yeast transformants co-
expressing either one of the E4 fusions plus the comple-
mentary ‘‘empty’’ DNA-binding or activation domain
showed only a background level of b-galactosidase ac-
tivity. Similarly, only a background level of activity was
detected when the DNA-binding domain alone, the acti-
vation domain alone, or both were expressed. These
results indicate that oligomeric interactions between
HPV 1 E4 molecules can bring the DNA-binding and
transcription activation domains into proximity at the
operator sequences of the lacZ reporter gene and acti-
vate expression of b-galactosidase.
FIG. 1. Schematic diagram of the structure of the LexA DNA-binding domain and B42 activation domain E1∧E4 fusions. In the B42 construct the
position of the SV40 large T antigen nuclear localisation signal (SV40 NLS) and the haemagglutinin epitope tag (HA epitope) are shown. The
N-terminus of the E1∧E4 protein is encoded by the E1 exon (E1). The leucine-rich motif, acidic/basic region, and the C-terminal homology domain are
highlighted. The structures of the HPV 1 E1∧E4 mutants inserted into the yeast two-hybrid system vectors are depicted below, with the name of the
mutant shown in the left-hand column.
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To test the specificity of the HPV 1 E4:E4 interaction
observed in this assay, yeast were transformed with
plasmids encoding a LexA–HPV 1 E1∧E4 fusion and a
B42–HPV 16 E1∧E4 fusion. There was no induction of
reporter gene activity (Table 1) indicating that the HPV 1
and 16 E4 proteins are unable to interact. This result
indicates that the b-galactosidase activity in yeast ex-
pressing both HPV 1 E4 LexA and B42 fusions is a
reflection of specific interactions between HPV 1 E4
molecules.
Sequences in the C-terminal half of the HPV 1 E1∧E4
protein are sufficient for E4 interactions
In order to define the region(s) within the E4 protein
sequence responsible for mediating E4 oligomeric inter-
actions, the full-length LexA–E4 fusion was coexpressed
with either N-terminal or C-terminal deletion mutants
fused to the B42 activation domain (Fig. 1 and Table 2).
Although the N-terminal deletion mutants, D2–15 and
D2–58, were capable of interacting with the full-length
B42–E4 fusion protein, the C-terminal deletion mutant
D61–125 failed to interact. Furthermore, yeast expressing
the N-terminal mutant D2–58 as both LexA and B42
fusions showed high levels of b-galactosidase activity,
similar to those observed in yeast expressing the full-
length E4 fusions. The corresponding experiment using
the D61–125 deletion fused to the DNA-binding domain
was not performed because it was not possible to sat-
isfactorily demonstrate stable expression of the LexA–
E4D61–125 construct by Western blot analysis (data not
shown). Taken together these results indicate that HPV 1
E4 sequences between residues 59–125 are sufficient to
mediate E4:E4 interactions in the two-hybrid assay.
In warts, the 10/11-kDa species encode the C-terminal
half of the E1∧E4 protein (Doorbar et al., 1988) and are
thought to arise by proteolytic cleavage of the E1∧E4
protein at amino acid 59 (Roberts et al., 1994a). Our
findings that the N-terminal deletion mutant, D2–58,
which is thought to resemble the 11-kDa polypeptide
expressed in warts, is able to interact both with the
full-length E1∧E4 protein and with itself in the two-hybrid
assay is consistent with previous observations that the
10/11-kDa E4 species are able to complex with them-
selves and with the 16/17-kDa polypeptides (Doorbar et
al., 1988, 1996; Roberts et al., 1994b).
HPV 1 E4 sequences between residues 95 and 115
mediate oligomeric interactions
HPV 1 E4 C-terminal sequences between residues 59
and 125 comprise an acidic-rich region (residues 64 to
80, part of a larger central charged region (residues 42 to
80)), followed by a region which shows significant se-
quence conservation in cutaneous HPV E4 proteins (res-
idues 90 to 120, Fig. 2A) (Roberts et al., 1994a). To
examine the importance of these different regions of the
C-terminal half of the HPV 1 protein in mediating E4:E4
interactions a series of small deletion mutants covering
the acidic region and the C-terminal homology domain
(Fig. 2B) were examined for their ability to interact with
the LexA–wild-type E4 fusion (Table 3). Deletion of acidic
residues 74–79 (EDEEKE) appeared to have little or no
effect on E4 self-association. Within the C-terminal ho-
mology domain deletion of residues 100–105, 105–110,
and 110–115 completely abolished E4:E4 interactions in
the two-hybrid assay. The deletion mutant D95-100
showed a level of b-galactosidase activity that was 10–
15% of that seen with the B42–wild-type E4 fusion, indi-
cating that this mutant can only interact weakly with the
wild type E4 protein. These results demonstrate that
sequences between residues 95 and 115 act as a major
determinant in HPV 1 E4 oligomeric interactions. The
deletion analysis of the acidic-rich region (residues 64 to
80) has not been comprehensive. While the results of the
interaction studies indicated that residues 74 to 79 are
not important we cannot exclude the possibility that
C-terminal sequences outside of the region 95 to 115
may also be involved in E4 oligomerisation.
TABLE 2
Interaction of N- and C-Terminal Deletion Mutants
in the Two-Hybrid Assay
DNA-binding domain Activation domain
b-Galactosidase activity
(U 6 SD)
LexA–E4 B42–E4D2–15 184.0 6 40.5
LexA–E4 B42–E4D2–58 196.2 6 41.7
LexA–E4 B42–E4D61–125 0.6 6 0.4
LexA–E4D2–58 B42–E4D2–58 213.2 6 56.6
TABLE 1
b-Galactosidase Activities of E4 Fusion Proteins
in the Two-Hybrid Assay
DNA-binding domain Activation domain
b-Galactosidase activitya
(U 6 SD)
LexA–Gal4b — 829.5 6 68.2
LexA — 2.0 6 0.6
LexA–E4c — 2.8 6 0.7
— B42 2.3 6 0.3
— B42–E4 4.1 6 1.2
LexA B42 2.1 6 1.2
LexA–E4 B42 2.4 6 0.7
LexA B42–E4 3.5 6 0.7
LexA–E4 B42–E4 197.3 6 30.9
LexA–E4 B42–HPV 16 E4 0.8 6 0.8
a Values for b-galactosidase activity are the mean of assays on at
least two individual transformants each assayed at least twice.
b LexA–Gal4 is a fusion of amino acids 1 to 87 of LexA fused to
residues 74 to 881 of the Gal4 protein. The fusion protein functions as
a transcriptional activator of reporter genes containing LexA operator
sequences.
c E4 fusions are HPV1 E1∧E4 fusions unless otherwise stated.
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Conserved hydrophobic residues are involved in
oligomeric interaction of the HPV 1 E4 protein
A feature of the C-terminal homology domain of cuta-
neous HPV E4 proteins is a conservation of hydrophobic
residues (Roberts et al., 1994a). Secondary structure pre-
dictions suggest that this region in the HPV 1 E4 protein
has a high a-helical content (Doorbar and Myers, 1996)
(Fig. 3). Representation of this region (residues 90 to 120)
with a helical wheel program indicates the relative ori-
entation of the amino acids if they were to form an
a-helix and predicts the formation of an amphipathic
helix with one face dominated by hydrophobic residues
(Fig. 3). Many of the residues which form this hydro-
phobic face are conserved between the cutaneous E4
proteins (Fig. 2A) and it is possible that hydrophobic
interactions are an important determinant of E4 oligo-
merisation. In order to assess the contribution of con-
served residues to E4 self-association and the putative
a-helical structure of this region, a small panel of single
and double mutations was constructed and assayed
using the two-hybrid system (Fig. 2A and Table 4).
Mutation of conserved hydrophobic residues in two
double mutations, I107SL111S and L111SF114N, com-
pletely abolished E4:E4 interactions in the assay, while
the single mutation L111S appeared to have little or no
effect. Both isoleucine 107 and phenylalanine 114 are
predicted to lie in the hydrophobic face of the helix.
Leucine 111 is at the edge and therefore may not signif-
icantly contribute to E4 self-association. In addition we
examined the influence of the conserved aspartates at
positions 110 and 112. The double mutation D110RD112R
had no effect on E4:E4 interactions, although deletion of
this region 110 to 112 (D110–112) completely abolished
E4 self-association, indicating that while the aspartic
acid residues are not important in oligomerisation, this
region of the protein is likely to form part of an important
structural motif. To test the putative a-helical structure of
TABLE 3
Interaction of C-Terminal E4 Deletion Mutants
with the Wild-Type LexA–E4 Fusion
Activation domain b-Galactosidase activity (U 6 SD)
B42–E4D74–79 222.8 6 72.6
B42–E4D90–95 138.5 6 67.8
B42–E4D95–100 24.5 6 6.6
B42–E4D100–105 0.9 6 0.7
B42–E4D105–110 3.0 6 1.3
B42–E4D110–115 1.3 6 0.7
B42–E4D115–120 220.8 6 44.4
FIG. 2. (A) The C-terminal sequence (residues 90 to 125) of the HPV 1 E1∧E4 protein is aligned with C-terminal sequences of other cutaneous E4 proteins.
Conserved residues are shaded. The position of residues mutated (single and double mutations) in the HPV 1 E4 protein are indicated by arrows. Adapted
from Roberts et al. (1994a). (B) The amino acid sequence of HPV 1 E4 residues 59 to 125 showing the position of the deletions tested in this study.
224 ASHMOLE, GALLIMORE, AND ROBERTS
the region 95 to 115, two nonconserved residues, threo-
nine 95 and glutamine 109, were separately substituted
by the a-helix disrupting amino acid proline. The Q109P
mutant showed a greatly reduced ability to interact with
wild-type E4, a result consistent with an a-helical struc-
ture. The T95P mutation, which is located at the periph-
ery of the region critical for E4 oligomerisation, showed
little or no reduction in ability to interact with the wild-
type protein.
Dimerisation of the HPV 1 E4 protein appears not to be
dependent on the formation of intermolecular disulphide
linkages (Doorbar et al., 1988; Roberts et al., 1994b).
Mutation of the single cysteine residue (C115A) in the
HPV 1 E4 protein did not abrogate the ability of the
mutant protein to interact with the wild-type E4 protein
(Table 4) further supporting a nonessential role for this
residue in oligomerisation, although it is unclear whether
disulphide linkage formation can occur in the environ-
ment of the yeast nucleus.
Levels of expression of B42–E4 constructs
The reduced ability of the mutant B42–E4 fusions to
interact with wild-type E4 could be a result of unstable
expression of the fusion protein. To examine this possi-
bility Western blot analysis of yeast cell extracts of all the
B42–E4 fusions (including the B42–HPV1 E4D61–125
and B42–HPV16 E4 fusions) was carried out. A repre-
sentative selection of these fusion proteins is shown in
Fig. 4. While levels of expression were variable, none of
the mutant fusions, including those showing a de-
creased E4:E4 interaction, were expressed at reduced
levels compared to the wild-type B42–E4 fusion. We
therefore conclude that any lack of reporter gene activity
was due to a genuine inability of E4 fusions to interact in
the assay, rather than an instability of B42–E4 fusion
proteins.
Chemical cross-linking experiments further indicate
the importance of HPV 1 E4 C-terminal sequences in
the formation of oligomers
Previous studies have shown that the HPV 1 E4 pro-
tein exists as soluble multimers (Doorbar et al., 1988,
1996). Our analysis using the yeast two-hybrid system
TABLE 4
Effect of Substitution Mutations within the Region of Residues 95–
115 on Interaction of E4 with the Wild-Type LexA–E4 Fusion
Activation domain b-Galactosidase activity (U 6 SD)
B42–E4I107SL111S 1.4 6 0.4
B42–E4L111SF114N 1.8 6 0.7
B42–E4L111S 156.3 6 52.0
B42–E4D11ORD112R 230.0 6 21.9
B42–E4D110–112 1.2 6 0.3
B42–E4C115A 231.9 6 21.2
B42–E4Q109P 42.9 6 5.6
B42–E4T95P 133.2 6 44.9
FIG. 3. (A) HPV 1 E1∧E4 C-terminal amino acid sequence 88 to 125. The region identified using the yeast two-hybrid system as important in E4
oligomerisation is boxed (residues 95 to 115). The extent of a-helical secondary structure is shown as arrows above the sequence. Secondary
structure prediction, adapted from Doorbar and Myers (1996), was made using the self-optimised prediction method (Geourjon and Deleage, 1994).
Solid black arrows indicate that these sequences have a high predicted ability to form a-helices; the lighter shaded arrow indicate a lower predicted
value. (B) Representation of the C-terminal residues 90 to 120 as a helical wheel. Hydrophobic residues are boxed and those conserved between E4
proteins of cutaneous types are indicated with an asterisk. Note the preponderance of hydrophobic residues on one face of the helix.
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indicates that residues 95 to 115 play a crucial role in
HPV 1 E4 oligomerisation. Since it is not possible to
identify the oligomerisation state of either the DNA-bind-
ing domain–E4 or the activation domain–E4 fusions used
in this system, it is unclear whether E4:E4 interactions at
the level of dimerisation or higher orders of oligomerisa-
tion are being examined. To further study the oligomeric
state of the HPV 1 E4 protein and the role of C-terminal
sequences, E4 protein purified from warts and from a
baculovirus expression system (Roberts et al., 1994b)
were cross-linked in the presence of the chemical cross-
linking agent DSP and the products were analysed by
SDS–PAGE.
The major species obtained by cross-linking of an E4
preparation purified from warts ran as a smear of ap-
proximate molecular weight 35–50 kDa (Fig. 5A, lanes 4
and 5). Though less distinct, a higher molecular weight
smear of between 70 and 100 kDa was also apparent. A
similar pattern of cross-linked species was observed
using recombinant baculovirus E4 protein. The major
species also ran as a smear of approximate molecular
weight 45–60 kDa and higher molecular weight species
of 100–130 kDa could also be detected (Fig. 5A, lanes 1
and 2). The size of the cross-linked complexes is con-
sistent with E4 existing in solution as a trimer (51 kDa).
Under the cross-linking conditions employed, all of the
E4 appeared to be present in an oligomeric state. No
monomeric (either 16/17 kDa or 10/11 kDa) or dimeric
(32/34 kDa) forms of E4 were visible on either Coo-
massie-stained gels (Fig. 5A) or by Western blotting (data
not shown). The diffuse appearance of the cross-linked
products suggests heterogenic structures which are
possibly a result of different degrees of intra- and inter-
molecular cross-linking. The slight differences in size of
the cross-linked species between the different sources
of E4 protein may reflect differences in posttranslational
modifications, e.g., proteolytic processing (Doorbar et al.,
1988) and phosphorylation (Breitburd et al., 1987; Grand
et al., 1989) of the two E4 preparations. It is interesting to
note the wart E4 preparation which forms slightly smaller
cross-linked products contains predominantly the pro-
cessed 10-, 11-, and 16-kDa E4 polypeptides (Fig. 5A,
lane 6).
In order to assess the stability of the E4 complexes,
cross-linking of recombinant E4 was performed in the
presence of increasing concentrations of urea (up to 9
M). Cross-linked E4 species were observed even at a
concentration of 6 M urea suggesting that the E4 com-
plexes are very stable in solution (Fig. 5B). Interestingly,
there was an increase in the molecular weight of the
cross-linked E4 species with increasing urea concentra-
tion. In the presence of 6 M urea the cross-linked E4
products were of approximate molecular weight 55–70
kDa, a size more consistent with a tetramer.
To investigate how proteins lacking C-terminal se-
quences behave in chemical cross-linking reactions, we
expressed and purified the deletion mutant D110–115
using a recombinant baculovirus. In the baculovirus sys-
tem this mutant protein was unstable relative to both
wild-type and other HPV 1 E4 mutant proteins we have
expressed using recombinant E4/baculoviruses (Roberts
et al., 1994b) and, consequently, we were unable to
obtain highly purified D110–115 protein preparations (Fig.
5C, lane 9). However, in the presence of the cross-linking
agent DSP the majority of the D110–115 protein remained
in the monomeric state (Fig. 5C, lanes 7 and 8). The
altered electrophoretic mobility of the monomeric form of
the protein was due to the reaction of E4 with the cross-
FIG. 4. Stability of B42–E4 (wild-type and mutant) fusion proteins. Cell lysates were prepared from yeast transformed with plasmids directing the
expression of the LexA–E4 (wild-type) and the B42–E4 (wild-type and mutant) fusion proteins and Western blotted using anti-HPV 1 (lanes 1–22) and
16 (lanes 23 and 24) antibodies. The yeast were grown on glucose SD medium which allows expression of the LexA–E4 fusion only (odd-numbered
lanes) or galactose/raffinose SD medium which allows expression of both the LexA–E4 and the B42–E4 fusions (even-numbered lanes). Lanes 1 and
2, wild-type HPV 1 E4; lanes 3 and 4, HPV 1 E4D90–95; lanes 5 and 6, HPV 1 E4D95–100; lanes 7 and 8, HPV 1 E4D100–105; lanes 9 and 10, HPV
1 E4D105–110; lanes 11 and 12, HPV 1 E4D110–115; lanes 13 and 14, HPV 1 E4D115–120; lanes 15 and 16, HPV 1 E4D2–15; lanes 17 and 18, HPV 1
E4D74–79; lanes 19 and 20, HPV 1 E4D110–112; lanes 21 and 22, HPV 1 E4D110RD112R; lanes 23 and 24, LexA HPV 1 E4 and B42–HPV 16 E4. The
position of the LexA–E4 and B42–E4 fusion proteins and molecular weight markers (kDa) are as indicated. All lanes were loaded with 100 mg of total
cellular protein.
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FIG. 5. Chemical cross-linking of HPV 1 E1∧E4 species purified from warts and from a baculovirus expression system. Samples were subjected
to SDS–PAGE and proteins visualised by Coomassie staining. (A) Lanes 1–3, baculovirus E4; lanes 4–6 wart E4, cross-linked in the presence of a
100-fold molar excess of DSP (lanes 1 and 4), a 50-fold molar excess of DSP (lanes 2 and 5), or in the absence of DSP (lanes 3 and 6). The positions
of the major cross-linked wart E4 (WE4) and baculovirus-expressed E4 (BcE4) species are indicated by vertical lines to the right of the figure. (B)
Chemical cross-linking of baculovirus E4 in the presence of a 50-fold molar excess of DSP (1) or in the absence of cross-linker (2) at urea
concentrations of 0, 2, 4, or 6 M as indicated. (C) Cross-linking of mutant HPV 1 E1∧E4 species: D10–14 (lanes 1–3), C115A (lanes 4–6), and D110–115
(lanes 7–9). The mutant proteins were cross-linked in the presence of a 100-fold molar excess of DSP (lanes 1, 4, and 7) or a 50-fold molar excess
of DSP (lanes 2, 5, and 8) or in the absence of cross-linker (lanes 3, 6, and 9). The proteins contaminating the D110–115 protein preparation are
indicated by arrows. The position of molecular weight markers (kDa) are as indicated.
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linker. Evidence from the yeast two-hybrid analysis (Ta-
ble 4) and from previous studies (Doorbar et al., 1988;
Roberts et al., 1994b) indicates that the cysteine residue
at position 115 does not play an essential role in E4
dimerisation. Cross-linking of a mutant protein contain-
ing a C115 3 A substitution also shows that it is not
essential for formation of higher orders of oligomers (Fig.
5C, lanes 4–6) indicating that covalent disulphide link-
ages do not play a major role in E4 oligomerisation. The
D10–14 mutant protein, which lacks the N-terminal
leucine-rich cluster (residues 10 to 14) important in me-
diating the interaction with the keratin cytoskeleton in
cultured epithelial cells (Roberts et al., 1994a), showed
no reduction in its ability to form high molecular weight
oligomers (Fig. 5C, lanes 1–3).
Taken together these cross-linking results indicate
that amino acid residues 110 to 115 are important for the
formation of multimeric E4 structures, possibly at the
level of dimerisation.
DISCUSSION
We have used the yeast two-hybrid system and chem-
ical cross-linking to characterise the structural require-
ments for oligomerisation of the HPV 1 E4 protein. The
results of the yeast two-hybrid analysis indicated that
amino acid residues 95 to 115, in the C-terminal half of
the protein, are critical for the formation of multimeric
complexes in vivo. Chemical cross-linking experiments
showed that the E4 protein exists as stable multimeric
complexes in solution, and a mutant protein containing a
deletion of residues 110 to 115 failed to multimerise
efficiently following cross-linking. The localisation of the
structural motif for oligomerisation to the C-terminus of
the HPV 1 E4 protein is consistent with previous reports
which have shown that the 10/11-kDa E4 species, which
encode the C-terminal half of the protein, form oligomers
in vivo (Doorbar et al., 1988, 1996; Roberts et al., 1994b).
Secondary structure predictive analysis of the HPV 1
E1∧E4 protein indicated that the C-terminal region has a
high a-helical content (Fig. 3). Representation of this
region as a helical wheel predicted an amphipathic helix
with one face dominated by hydrophobic residues. Mu-
tational analysis of this region showed that hydrophobic
residues predicted to lie in the hydrophobic face play a
major role in E4 oligomerisation (Table 4). While the
C-terminal region may not form a single uninterrupted
a-helix, the results presented here are consistent with a
model of E4 oligomerisation in which a-helical region(s)
of the C-terminus mediates multimerisation through in-
teractions between hydrophobic faces or patches of the
helix(es). These sequences form part of a C-terminal
domain which is conserved between E4 proteins of other
cutaneous HPV types (Fig. 2) suggesting that the pro-
posed model of E4 self-association may be common to
all cutaneous E4 proteins. The C-terminal region of mu-
cosal HPV E4 proteins also shows a level of sequence
conservation (Zhu et al., 1994; Roberts et al., 1997),
though there is little or no homology between these
domains of cutaneous and mucosal E4 proteins (Zhu et
al., 1994). Interestingly, mutation of conserved hydropho-
bic residues within the HPV 16 E1∧E4 C-terminal region
reduces the ability of the protein to form insoluble oligo-
meric complexes, suggesting that hydrophobic residues
also play a role in mediating HPV 16 E4:E4 interactions
(Roberts et al., 1997).
An alternative explanation of the data presented in this
study is that mutations within the C-terminal homology
domain may induce global perturbation of the structure
of the E4 molecule, masking or disrupting sequences
elsewhere in the protein which are involved in mediating
self-association. Several factors argue against this inter-
pretation of the data. First, no mutations outside of the
C-terminal region 95 to 115 have been identified as
disrupting E4:E4 interactions. Second, point mutations
which are less likely to induce structural alterations than
deletions also abrogate oligomerisation. Finally, all of the
E4 mutants examined in this study were expressed as
stable B42–E4 fusions (Fig. 4) indicating that the overall
structural integrity of the HPV 1 E4 molecule is unlikely to
have undergone gross alteration.
We have used chemical cross-linking of E4 protein
purified from warts and from a baculovirus expression
system to assess the level of E4 oligomerisation exam-
ined in the two-hybrid assay (Fig. 5). The major cross-
linked E4 complexes we identified were 35–50 kDa (wart
E4) and 45–60 kDa (baculovirus-expressed E4). These E4
complexes were formed in the presence of high concen-
trations of urea (up to 6 M) indicating that they are very
stable and that noncovalent interactions stabilising them
may be strong. The size of these complexes is similar to
the 58-kDa E4 complex observed by Doorbar et al.,
(1996). There is an apparent disparity in the size of the
complexes detected by us and others and that predicted
for HPV 1 E4 multimers (51 kDa for a trimer and 68 kDa
for a tetramer). However, in this study an increase in the
molecular weight of the cross-linked E4 complexes to
55–70 kDa, a size more consistent with a tetrameric
complex, was observed following cross-linking in the
presence 6 M urea (Fig. 5B).
The mutant protein containing a deletion of residues
110 to 115 (D110–115), purified from insect cells, re-
mained in a monomeric form following cross-linking (Fig.
5C). This result suggests that this part of the C-terminal
self-association domain is important in the formation of
dimers, rather than higher orders of oligomerisation.
Whether the C-terminal self-association domain (95 to
115) is involved in the formation of higher orders of E4:E4
interactions, and the possible role of posttranslational
modifications, e.g., zinc binding (Roberts et al., 1994b)
and phosphorylation (Breitburd et al., 1987; Grand et al.,
1989), will require further investigation.
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The precise function of the E4 protein in the virus life
cycle is only poorly understood and therefore the role of
oligomerisation in E4 function is difficult to evaluate.
Currently, the only assayable function of the E4 proteins
is the association between E4 and the keratin cytoskel-
eton of cultured keratinocytes (Doorbar et al., 1991; Rob-
erts et al., 1993; Rogel-Gaillard et al., 1993; Sterling et al.,
1993). E4 oligomerisation does not appear to be essen-
tial for the interaction with the cytoskeleton as mutant
proteins containing deletions across the E4 self-associ-
ation domain retained the ability to interact with the
keratin networks (Roberts et al., 1994a). However, the
affinity for the keratin cytoskeleton appears to be re-
duced and, furthermore, the D110–115 protein induces a
reorganisation of the networks suggesting that the C-
terminal sequences, and therefore possibly oligomerisa-
tion, do play some role in the interaction. We have re-
ported similar findings for the HPV 16 E4 protein (Roberts
et al., 1997). Taken together these results suggest that E4
oligomerisation is likely to have a role in E4 function.
In conclusion, we have identified sequences 95 to 115
within the C-terminal homology domain of HPV 1 E4 as
critical to oligomerisation and have proposed a model for
E4 self-association which involves conserved hydropho-
bic residues.
MATERIALS AND METHODS
Yeast strains and methods
The yeast strain S. cerevisiae EGY48 (Mat a ura3 his3
trp1 LEU2<LexAop6-Leu2) was used in this study.
EGY48 and the plasmid components of the yeast two-
hybrid system were kindly provided by Roger Brent (Har-
vard University). Yeast transformation was by the method
of Schiestl and Gietz (1989). Cells were grown in YPD
medium (1% yeast extract, 2% peptone, 2% glucose) or
SD medium (0.67% yeast nitrogen base, 2% glucose
containing the appropriate amino acid supplement), ex-
cept under induction conditions where 2% glucose was
substituted by 2% galactose, 1% raffinose in the SD
medium.
Plasmid constructs
The LexA DNA-binding domain fusions were con-
structed in the vector pEG202 and the B42 activation
domain fusions were constructed in the vector pJG4-5
(Gyuris et al., 1993). pEG202 contains the yeast select-
able marker HIS3. Expression of the LexA fusion protein
is driven from the constitutively active yeast ADH1 pro-
moter. DNA sequences cloned into pJG4-5 are ex-
pressed as fusion proteins to the influenza haemagglu-
tinin 1 epitope tag, the B42 activation domain, and the
nuclear localisation signal of the Simian virus 40 (SV40)
large T antigen. Expression from the GAL1 promoter in
this vector is induced in the presence of galactose and
repressed by glucose. pJG4-5 contains the yeast select-
able marker TRP1.
DNA-binding domain–E4 and activation domain–E4 fu-
sion proteins were constructed by polymerase chain
reaction (PCR) amplification of E4 coding sequences of
wild-type and mutant HPV 1 E1∧E4 cDNAs (Roberts et al.,
1993, 1994a) using the forward primer 59 TTCATGGCA-
GATAATAAAGCT 39 (P1) and the reverse primer 59
TTCGTCAAAGTCAACTTGAG 39 (P2) except for the dele-
tion mutant D2–58 which was constructed using the
primer pair 59 TTCATGGCAGACGGCCTTACG 39 and P2.
The N-terminal deletion mutant D2–15 was amplified
using the primer pair 59 TTCATGTACACTCCGACTACC 39
and P2, and the C-terminal deletion mutant D61–125 was
constructed using the forward primer P1 and the reverse
primer 59 TTCTATTAGTCTGCGTACAGGTGT 39. New mu-
tations constructed for this study were generated by
oligonucleotide-directed in vitro mutagenesis as de-
scribed by us previously (Roberts et al., 1994b). The HPV
16 E1∧E4 activation domain fusion was constructed from
an HPV 16 E1∧E4 cDNA (Roberts et al., 1993) by PCR
amplification using the forward primer 59 TTCATGGCT-
GATCCTGCAGCA 39 and the reverse primer 59 TTC-
GCAGTATACAATGTACA 39. The primers contain half of
an EcoRI recognition site (underlined) and therefore prior
to cloning into the EcoRI site of pEG202 and/or pJG4-5,
the PCR product was phosphorylated and the product
concatermerised by T4 DNA ligase and the correct ter-
mini were recreated after cleavage with EcoRI. All mutant
cDNAs and PCR products were sequenced in their
entirety.
b-galactosidase activation assay
The yeast strain EGY48 was transformed with the
URA31 lacZ reporter plasmid pSH18-34 (a gift of Steve
Hanes, Massachusetts General Hospital, Boston, MA).
EGY48/pSH18-34 cells were transformed with the indi-
cated DNA-binding domain and activation domain E4
fusions and selected for growth on glucose minimal
medium deficient in uracil, histidine, and tryptophan.
Individual yeast transformants were patched onto galac-
tose/raffinose minimal medium plates lacking the appro-
priate amino acids and grown overnight before removing
an amount of culture sufficient to give an optical density
at 600 nm of between 1.0 and 2.0 when resuspended in
1.0 ml of Z buffer (60 mM disodium orthophosphate, 40
mM sodium orthophosphate, 10 mM potassium chloride,
1 mM magnesium sulphate, 50 mM b-mercaptoethanol,
pH 7.0) (Miller, 1972). Fifty microlitres of resuspended
culture was made up to 1 ml with Z buffer and taken for
b-galactosidase activity determination as described by
Miller (1972). Briefly, yeast was permeabilised by vortex-
ing in the presence of 50 ml 0.1% (w/v) SDS and 75 ml
chloroform, before commencing the reaction by the ad-
dition of 200 ml of a 4 mg/ml solution of o-nitrophenyl
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b-D-galactoside in Z buffer. Samples were incubated at
28°C for 60 min before stopping the reaction by the
addition of 0.5 ml of 1 M sodium carbonate. b-Galacto-
sidase activity was calculated from the absorbance at
420 nm of each sample.
Preparation of HPV 1 E4 protein from warts
E4 protein was extracted in the presence of phos-
phate-buffered saline (PBS) from HPV 1-induced wart
skin parings and purified by affinity chromatography as
previously described (Roberts et al., 1994b).
Expression of wild-type and mutant HPV 1 E4
proteins in insect cells
Wild-type and mutant HPV 1 E4 recombinant baculo-
viruses were constructed and propagated as described
by us previously (Roberts et al., 1994b). Sf-9 cells were
infected with the recombinant baculoviruses and E4 pro-
tein purified by affinity chromatography as described
(Roberts et al., 1994b).
Chemical cross-linking
Wild-type and mutant HPV 1 E4 proteins, purified from
warts and insect cells (see above), were cross-linked
using dithiobis(succinimidyl propionate) (DSP, Pierce
Chemical Co.). Ten-microgram aliquots of E4 protein in
10 mM HEPES, pH 7.8, or PBS were cross-linked using a
50- or 100-fold molar excess of DSP (prepared immedi-
ately before use as a 20 mM stock solution in DMSO) in
a reaction volume of 20–30 ml. Cross-linking reaction
mixes were incubated for 30 min at 20°C and then
quenched by the addition of 1 M Tris–HCl, pH 7.5, to a
final concentration of 50 mM. An equivalent volume of
DMSO without cross-linker was added to control sam-
ples. Cross-linked samples were mixed with an equal
volume of SDS–PAGE sample buffer lacking b-mercap-
toethanol (6% SDS, 25% glycerol, 0.01% bromophenol
blue, 50 mM Tris–HCl, pH 6.8) and boiled for 3 min prior
to electrophoresis on an 8% SDS–polyacrylamide gel.
Proteins were visualised by Coomassie blue staining.
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